Lidocaine Hydrochloride Bp Mercury Pharmaceuticals (Lidocaine Hydrochloride)

Lidocaine blocks voltage‑gated sodium channels on neuronal and cardiac cell membranes, preventing the rapid influx of sodium that initiates action potentials. This inhibition stops the propagation of nerve impulses, producing local anaesthesia, and suppresses abnormal cardiac electrical activity, helping to control arrhythmias.

The dosage of lidocaine Hydrochloride Bp is determined by the prescribing clinician based on the specific procedure, patient weight, age, and clinical condition. Healthcare professionals calculate the appropriate amount and administration rate to ensure safety and efficacy.

Safety data for lidocaine Hydrochloride Bp in pregnancy and lactation are limited, and the pregnancy category is listed as unknown. Clinicians should evaluate the potential benefits against possible risks before prescribing to pregnant or nursing patients.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lidocaine is an amide‑type local anesthetic with a rapid onset and moderate duration, making it suitable for short‑to‑moderate procedures. Compared with ester‑type agents, it generally has a lower risk of allergic reactions and is metabolised hepatically, allowing predictable clearance in most patients.

Lidocaine Hydrochloride Bp should be stored below 25 °C, in its original packaging, protected from light and moisture. Maintaining these conditions preserves the solution’s stability and potency throughout its shelf life.

The product is supplied as a sterile injectable solution for intravenous use. Administration is performed by a qualified healthcare professional, who injects the solution directly into a vein, typically using an infusion pump or controlled syringe to manage the rate and total dose.

Serious risks include seizures, severe cardiac arrhythmias or arrest, and anaphylactic reactions. These events are rare but require immediate medical intervention. Monitoring of cardiac and neurological status during and after administration helps mitigate these risks.

Patients with known hypersensitivity to amide‑type local anesthetics, those with severe hepatic impairment, or individuals taking interacting Class I antiarrhythmics or strong CYP3A4 inhibitors should avoid lidocaine Hydrochloride Bp unless a risk‑benefit assessment justifies its use.